Authored By: Sarah
11 Jul 2024

 Bispecific Antibodies For Cancer Market Size to grow by USD 314.3 million between 2024-2028

According to a research report “ Bispecific Antibodies For Cancer Market” by Type (CD19 or CD3, CD30 or CD16A) Distribution Channel (Hospitals, Retail pharmacies, Online) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 314.3 million, at a CAGR of  6.78% during the forecast period. The global burden of cancer continues to rise, with it being the second-leading cause of death worldwide. This disease is characterized by uncontrolled cell division due to genetic damage, leading to the destruction of normal body cells and tissues. Major types of cancer include sarcomas, carcinomas, melanomas, leukemia, and lymphomas. In Asia, the prevalence of cancer is projected to reach 10.6 million cases by 2030. In the US, breast, cervical, and prostate cancers are prevalent, while breast, prostate, and lung cancers are the most common types. The escalating cancer incidence globally serves as a significant growth driver for the bispecific antibodies market, which offers promising therapeutic solutions for various cancer types.

Browse market data tables, figures, and in-depth TOC on “Bispecific Antibodies For Cancer Market” by Type (CD19 or CD3, CD30 or CD16A) Distribution Channel (Hospitals, Retail pharmacies, Online) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Type, the CD19 or CD3 segment is projected to dominate the market size in 2024

In the healthcare sector, hospitals serve as significant end-users of bispecific antibodies for cancer, significantly contributing to the expansion of the global market. Major hospital infrastructure consists of multispecialty hospitals and hospital groups, which are funded by government sponsorship or private entities and accommodate over 500 hospital beds. The increasing number of hospital admissions due to cancer diagnoses will lead to a surge in demand for neuroscience antibodies and assay products in these institutions. This trend is expected to propel the growth of the global bispecific antibodies for cancer market throughout the forecast period.

By Distribution Channel, Hospitals  segment is expected to hold the largest market size for the year 2024

The prevalence of acute lymphoblastic leukemia (ALL), particularly in the CD19 or CD3 segment, is driving growth in the bispecific antibodies for cancer market. ALL is most commonly diagnosed in children, adolescents, and young adults, with the National Cancer Institute projecting that 6,550 new cases will be diagnosed in the US in 2024, and 1,330 of these individuals will unfortunately succumb to the disease. This increasing incidence has led to a heightened demand for innovative treatments. One such promising solution is Blinatumomab, a CD19 or CD3 bispecific antibody (bsAb) developed in the BiTEs format, which offers a novel approach to targeting cancer cells and improving patient outcomes.

North America is forecasted to hold the largest market size by region in 2024

The Bispecific Antibodies for Cancer market represents a significant growth opportunity for pharmaceutical and biotech companies. These innovative therapeutics, which bind to two distinct targets, offer enhanced specificity and efficacy in cancer treatment. With numerous clinical trials underway, the market is poised for substantial expansion, providing a lucrative business proposition for industry players.

The Bispecific Antibodies For Cancer Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • ABL Bio Inc.
  • Akeso Inc.
  • Amgen Inc.
  • Aptevo Therapeutics Inc.
  • Astellas Pharma Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Johnson and Johnson Services Inc.
  • Mereo BioPharma Group Plc
  • Merus N.V.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • TG Therapeutics Inc.
  • Vadilal Industries Ltd.
  • Y mAbs Therapeutics Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The bispecific antibodies market is experiencing significant growth due to technological advancements in cancer treatment. Bispecific antibodies, which can bind to two distinct antigens, offer unique advantages over traditional monoclonal antibodies. Two notable examples are Ozoralizumab and Tibulizumab, which are being developed for multiple sclerosis and multiple myeloma, respectively. However, the bispecific antibodies market faces challenges. Diverted resources and supply chain challenges have arisen due to the increasing focus on COVID-19 treatments. Additionally, clinical trials for bispecific antibodies in indications such as Crohn's disease, psoriasis, mental health disorders, and other cancers are ongoing. The potential market size for bispecific antibodies in adult Americans with cancer is estimated to reach USD8 trillion by 2027. With the growing demand for targeted therapies, the bispecific antibodies market is expected to continue its upward trajectory, despite the current challenges. Biologic therapies, including bispecific antibodies, are revolutionizing cancer treatment and offering new hope for patients.

Market Research Overview

The bispecific antibodies market is witnessing significant developments in the cancer segment, driven by the precision medicine approach and regulatory environment. Companies like Genentech are leading the charge with innovative bispecific antibodies such as Ozoralizumab and Tibulizumab for Lymphoma and multiple sclerosis, Crohn's disease, psoriasis, and rheumatoid arthritis, respectively. These advancements in technologies and complementary expertise have piqued the interest of regulatory bodies and increased confidence in the efficacy of these therapies. However, the bispecific antibodies market faces challenges such as strained healthcare systems, diverted resources, and supply chain challenges. The high cost of biologic therapies, estimated to reach USD8 trillion for adult Americans alone by 2027, and the need for clinical trials to address mental health disorders, infectious diseases, and autoimmune disorders add to the complexity. Despite these challenges, the potential for targeted therapies in cancer treatment and the advancements in the regulatory environment offer significant opportunities for growth in the bispecific antibodies market. Multiple myeloma, a type of cancer, is a significant focus area for bispecific antibodies, with ongoing clinical trials exploring their potential in treating this condition. The healthcare expenditure on cancer treatment is expected to increase, making the bispecific antibodies market an attractive investment opportunity for companies and investors alike.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!